Teimouri Samaneh, Deravi Niloofar, Khazaei Afshin, Belbasi Mohaddeseh, Taheri Mahbobe, Rahimi Mitra, Mostafazadeh Babak, Erfan Talab Evini Peyman, Shadnia Shahin
Department of Clinical Toxicology, School of Medicine Toxicological Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Students Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Arch Acad Emerg Med. 2025 May 25;13(1):e50. doi: 10.22037/aaemj.v13i1.2534. eCollection 2025.
Lead poisoning can present with a spectrum of symptoms, from fatigue to severe multiorgan complication; and Zeolite is known for its ability to remove heavy metals. This study aimed to assess the impact of zeolite on serum lead levels and blood parameters of patients with mild to moderate lead poisoning.
This double-blind randomized clinical trial evaluated the effects of zeolite on serum lead levels of patients with mild to moderate lead poisoning, conducted between August 2022 and December 2022. The intervention group received oral zeolite tablets in addition to standard treatment, while the control group received only standard treatment. The impact of zeolite administration on serum lead levels and blood parameters was investigated using an appropriate statistical test.
80 patients with a mean age of 39.84 ± 11.94 (range: 23-75) years were randomized (78.75% male). The two groups were similar regarding age (p = 0.329), sex (p = 0.785), baseline serum lead levels (p = 0.596), and liver enzymes (p = 0.648).The Zeolit group had lower serum lead levels (25.22 ± 13.26 vs. 37.68 ± 15.34; p < 0.001, ES: 0.869) and hematocrit (36.21 ± 7.83 vs. 39.53 ± 5.60; ES: 0.488; p = 0.032) after 2 weeks of treatment.
Zeolite tablets show considerable promise as an adjunct therapy for mild to moderate lead poisoning. They effectively lower serum lead levels without adverse effects. This intervention could reduce the metal burden in the bloodstream and mitigate lead-induced multiorgan damage, offering a more effective and less invasive treatment option.
铅中毒可表现出一系列症状，从疲劳到严重的多器官并发症；而沸石以其去除重金属的能力而闻名。本研究旨在评估沸石对轻度至中度铅中毒患者血清铅水平和血液参数的影响。
这项双盲随机临床试验评估了2022年8月至2022年12月期间沸石对轻度至中度铅中毒患者血清铅水平的影响。干预组在标准治疗的基础上口服沸石片，而对照组仅接受标准治疗。使用适当的统计检验研究了给予沸石对血清铅水平和血液参数的影响。
80例患者被随机分组，平均年龄为39.84±11.94（范围：23 - 75）岁，其中男性占78.75%。两组在年龄（p = 0.329）、性别（p = 0.785）、基线血清铅水平（p = 0.596）和肝酶（p = 0.648）方面相似。治疗2周后，沸石组的血清铅水平较低（25.22±13.26 vs. 37.68±15.34；p < 0.001，效应量：0.869），血细胞比容也较低（36.21±7.83 vs. 39.53±5.60；效应量：0.488；p = 0.032）。
沸石片作为轻度至中度铅中毒的辅助治疗方法显示出巨大的前景。它们能有效降低血清铅水平且无不良反应。这种干预措施可以减轻血液中的金属负担，减轻铅引起的多器官损伤，提供一种更有效且侵入性较小的治疗选择。
